Oncodesign Precision Medicine (XPAR:ALOPM) Operating Margin %: -1,319.33% (As of Dec. 2025)


XPAR:ALOPM Oncodesign Precision Medicine SA XPAR:ALOPM
33 GF Score
Price €0.34
GF Value €0.29
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Operating Margin %?

Oncodesign Precision Medicine XPAR:ALOPM +3.94% 33 Operating Margin % is -1,319.33% as of Dec. 2025. GuruFocus rates XPAR:ALOPM with a GF Score™ of 33/100 and a GF Value™ of €0.29 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 937 Biotechnology companies, Oncodesign Precision Medicine ranks better than 99.68% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Oncodesign Precision Medicine's Operating Income for the six months ended in Dec. 2025 was €-1.57 Mil. Oncodesign Precision Medicine's Revenue for the six months ended in Dec. 2025 was €0.12 Mil. Therefore, Oncodesign Precision Medicine's Operating Margin % for the quarter that ended in Dec. 2025 was -1,319.33%.

The historical rank and industry rank for Oncodesign Precision Medicine's Operating Margin % or its related term are showing as below:

XPAR:ALOPM' s Operating Margin % Range Over the Past 10 Years
Min: -3771.5   Med: -118.79   Max: 3148.66
Current: 3148.66


XPAR:ALOPM's Operating Margin % is ranked better than
99.68% of 937 companies
in the Biotechnology industry
Industry Median: -86.33 vs XPAR:ALOPM: 3148.66

Oncodesign Precision Medicine's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Oncodesign Precision Medicine's Operating Income for the six months ended in Dec. 2025 was €-1.57 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €8.22 Mil.


Oncodesign Precision Medicine  (XPAR:ALOPM) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Oncodesign Precision Medicine Operating Margin % Related Terms


Oncodesign Precision Medicine Operating Margin % Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Operating Margin % Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -97.76 -20.17 -927.61 -3,771.50 3,148.66

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,568.81 -2,969.72 -5,523.08 6,892.96 -1,319.33

XPAR:ALOPM vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Oncodesign Precision Medicine's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Operating Margin % falls into.


XPAR:ALOPM
33GF Score
Oncodesign Precision Medicine SA XPAR:ALOPM
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Oncodesign Precision Medicine's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=8.218 / 0.261
=3,148.66 %

Oncodesign Precision Medicine's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-1.57 / 0.119
=-1,319.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -1,319.33% mean?
Oncodesign Precision Medicine (XPAR:ALOPM) has a Operating Margin % of -1,319.33% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Oncodesign Precision Medicine and its competitors. According to the industry distribution chart, Oncodesign Precision Medicine ranks #3 out of 937 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Oncodesign Precision Medicine's Operating Margin % too high?
Oncodesign Precision Medicine's current Operating Margin % is -1,319.33%. Based on the distribution chart, Oncodesign Precision Medicine ranks #3 out of 937 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 33/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #3 out of 937 companies for Operating Margin %. This places Oncodesign Precision Medicine in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Operating Margin % is -1,319.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.29, compared to a current price of €0.34 — trading 18.3% above its estimated fair value. The current Operating Margin % is -1,319.33%. Oncodesign Precision Medicine's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current Operating Margin % is -1,319.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.34 is trading 18.3% above its estimated GF Value™ of €0.29. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for XPAR:ALOPM:

  • Operating Margin %: -1,319.33%
  • GF Value™: €0.29 vs. price of €0.34 (18.3% above fair value)
  • GF Score™: 33/100 with 1 warning sign

No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncodesign Precision Medicine Business Description

Other Exchanges ZR8:Germany
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score

Get the complete analysis for XPAR:ALOPM

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price
€0.29
GF Value